Articles Vol. 65 No. CĐ 3 - Bệnh viện Phổi Trung ương 15/05/2024

35. EVALUATING THE RESULT LINE 1 OF TREATMENT NON SMALL CELL LUNG CANCER PATIENTS STAGE IV HABOR EGFR MUTATION BY OSIMERTINIB AT NATIONAL LUNG HOSPITAL FROM 2019 TO 2022

Phuong Ngoc Anh1,2, Dinh Ngoc Viet1,2, Hoang Thi Bich Viet1,2, Can Xuan Hanh1,2
1 National Lung Hospital
2 Bệnh viện Phổi Trung ương
Corresponding author: Phuongngocanhhmu@gmail.com
DOI: 10.52163/yhc.v65iCD3.1132
18 Views
9 Downloads
Keywords
Osimertinib, tagrisso lung cancer, EGFR mutations, progression-free survival, side effects, overall survival.
Abstract

Objectives: (1) To evaluate the rate of response and the period time of progression-free survival. (2) To evaluate side effects of Osimertinib.

Methods: Cross-sectional descriptive study 31 adenonocarcinoma lung cancer harboring EGFR mutations patients at National Lung Hospital, from December 2019 to August 2023.

Results: The mean of age is : 63,42 ± 9,36 age, the youngest is 40 and the oldest is 85 age, female/male is 1,07/1, the most common symptom is chest pain with 26 patients. The most common location metastasis is pleural with 18 patinents. EGFR mutations at exon 19 is the common than at exon 21 with rate 19/11, one patient habor T790M mutation. Overall response rate (ORR) is 70,9 % with 61,3% is partial response. The mean progression-free survival is 20,70 ± 3,32 months, median PFS is 15,67 months with minimum is 3,19 months and maximum is 44,16 months. The most common treatment accompanied is Zoledronic acid with 11 patients. Recording side effects, rash on skin is the most common with rate is 48,4 %, most of them are grade I. Side effects with increasing aspartat transaminase and alanin transaminase grade I with 8 patients (25,8%) and all side effects: No patients with grade III or grade IV.

Conclusion: Treatment by target drug as Osimertinib with patients adenocarcinoma lung cancerstage IV harboring EGFR mutations has high overall response rate : 70,9%, median progression-free survival is 15,67 months. Side effects are often mild. So with adenocarcinoma lung cancer harboring EGFR mutations, we should treatment by Osimertinib, special in old patients, who has not good performance status, can not treatment with chemotherapy.

References
[1]
Mok T.S., Wu Y.-L., Ahn M.-J. et al., Osimertinib Google Scholar
[2]
or Platinum–Pemetrexed in EGFR T790M– Google Scholar
[3]
Positive Lung Cancer. N Engl J Med, 376(7), Google Scholar
[4]
, 629–640. Google Scholar
[5]
Soria J.-C., Ohe Y., Vansteenkiste J. et al., Google Scholar
[6]
Osimertinib in Untreated EGFR-Mutated Advanced Google Scholar
[7]
Non–Small-Cell Lung Cancer. N Engl J Med, Google Scholar
[8]
(2), 2018, 113–125. Google Scholar
[9]
Wu Y.-L., Tsuboi M., He J. et al., Osimertinib Google Scholar
[10]
in Resected EGFR-Mutated Non–Small-Cell Google Scholar
[11]
Lung Cancer. N Engl J Med, 383(18), 2020, Google Scholar
[12]
–1723. Google Scholar
[13]
FDA Approves Tagrisso (osimertinib) for EGFR Google Scholar
[14]
T790M Mutation-Positive Non-Small Cell Lung Google Scholar
[15]
Cancer. Drugs.com, <https://www.drugs.com/ Google Scholar
[16]
newdrugs/fda-approves-tagrisso-osimertinibegfr- Google Scholar
[17]
t790m-mutation-positive-non-small-celllung-cancer- Google Scholar
[18]
html>, accessed: 29/09/2022. Google Scholar
[19]
FDA Approves Tagrisso (osimertinib) as FirstLine Google Scholar
[20]
Treatment for EGFR-Mutated Non-Small Google Scholar
[21]
Cell Lung Cancer. Drugs.com, Google Scholar
[22]
drugs.com/newdrugs/fda-approves-tagrisso-osimertinib- Google Scholar
[23]
first-line-egfr-mutated-nonsmall-cell-lung-cancer- Google Scholar
[24]
html>, accessed:24/09/2022. Google Scholar
[25]
Tagrisso Approved in the US for the Adjuvant Google Scholar
[26]
Treatment of Patients with Early-Stage EGFR-Mutated Google Scholar
[27]
Non-Small Cell Lung Cancer. Google Scholar
[28]
Drugs.com, <https://www.drugs.com/newdrugs/ Google Scholar
[29]
tagrisso-approved-us-adjuvant-patients-earlystage- Google Scholar
[30]
egfr-mutated-non-small-cell-lung-cancer-5411.html>, Google Scholar
[31]
accessed: 29/09/2022. Google Scholar
[32]
Onoi K., Kaneko Y., Uchino J. Osimertinib in Google Scholar
[33]
first line setting: For Asian patients. Transl Lung Google Scholar
[34]
Cancer Res, 8(4), 2019. Google Scholar